In This Article:
The U.S. market is currently experiencing heightened volatility, with major indices like the Dow Jones and Nasdaq Composite facing declines due to renewed trade tensions following President Trump's recent tariff threats against the EU and Apple. In this environment, identifying high-growth tech stocks requires a focus on companies that demonstrate resilience through innovation and adaptability amidst shifting economic policies and global trade uncertainties.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 26.38% | 39.09% | ★★★★★★ |
| Ardelyx | 20.78% | 59.46% | ★★★★★★ |
| Travere Therapeutics | 26.41% | 64.47% | ★★★★★★ |
| Blueprint Medicines | 21.36% | 61.45% | ★★★★★★ |
| TG Therapeutics | 26.46% | 38.75% | ★★★★★★ |
| Alnylam Pharmaceuticals | 23.65% | 61.11% | ★★★★★★ |
| AVITA Medical | 27.28% | 60.66% | ★★★★★★ |
| Alkami Technology | 20.54% | 76.67% | ★★★★★★ |
| Ascendis Pharma | 35.16% | 60.26% | ★★★★★★ |
| Lumentum Holdings | 21.59% | 110.32% | ★★★★★★ |
Click here to see the full list of 237 stocks from our US High Growth Tech and AI Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Bit Digital
Simply Wall St Growth Rating: ★★★★★☆
Overview: Bit Digital, Inc., along with its subsidiaries, operates in the bitcoin mining industry and has a market capitalization of $502.52 million.
Operations: The company is involved in bitcoin mining, focusing on generating revenue through the production of bitcoin. With a market capitalization of $502.52 million, its business model revolves around leveraging its mining operations to capitalize on the cryptocurrency market.
Despite recent setbacks, Bit Digital's aggressive expansion into AI infrastructure, highlighted by its new data center in Quebec and a significant partnership with Cerebras Systems, underscores its strategic pivot towards high-growth sectors. This move is particularly notable as the company navigates through a challenging phase marked by a substantial net loss of $57.71 million in Q1 2025 and a sharp revenue drop from the previous year. However, with an expected annual profit growth of 103% and revenue growth forecasts outpacing the market at 34.6%, Bit Digital is positioning itself to capitalize on burgeoning tech trends, albeit amidst financial volatility and shareholder dilution concerns from recent equity offerings.
-
Click here and access our complete health analysis report to understand the dynamics of Bit Digital.
-
Gain insights into Bit Digital's historical performance by reviewing our past performance report.
ADMA Biologics
Simply Wall St Growth Rating: ★★★★☆☆
Overview: ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for treating immune deficiencies and infectious diseases globally, with a market cap of $4.80 billion.